The Court had raised questions over the spread between purchase prices and MRP and whether the existing 16% margin cap for scheduled drugs could be extended to a wider set of medicines. The matter is scheduled for another hearing on October 12, 2026.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.